This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schwartz, J. L. Articles by Weichselbaum, R. R. Search for Related Content PubMed PubMed Citation Articles by Schwartz, J. L. Articles by Weichselbaum, R. R.

X-Ray and cis-Diamminedichloroplatinum(II) Cross-Resistance in Human Tumor Cell Lines¹

Departments of Radiation and Cellular Oncology [J. L. S., M. A. B., D. R. J., M. T., S. M. G., J. M., R. R. W.], and Obstetrics and Gynecology [J. R.], University of Chicago Medical Center, Chicago, Illinois 60637

Clinical studies have suggested a close correlation between cis-diamminedichloroplatinum(II) (cisplatin) and radiation resistance. To determine whether this cross-resistance is due to an inherent cellular resistance to both agents, ten early passage human tumor cell lines were examined for their radiation and cisplatin sensitivity in vitro. Previous studies have suggested that these early passage tumor cell lines retain many of their in vivo characteristics and are therefore good models for tumor cells in vivo. Radioresistance was strongly associated with cisplatin resistance in these cell lines. Four of the cell lines examined were radioresistant, having D₀s > 2.0 Gy. These four lines were also resistant to cisplatin, with the dose reducing survival to 10% > 1.29 µM. The remaining six cell lines had D₀s ranging from 1.07 to 1.57 Gy of X-ray and doses reducing survival to 10% of less than 0.83 µM cisplatin. Because early passage human tumor cell lines were used, resistance or sensitivity to radiation and cisplatin most likely developed in vivo and was not due to selection in vitro. These results indicate that cross-resistance between cisplatin and radiation in vivo is probably due primarily to an inherent cellular resistance to these agents and not necessarily to the tumor microenvironment in situ.

¹ This investigation was supported by Grant CA 42596 awarded by the National Cancer Institute.

² To whom requests for reprints should be addressed.

Received 1/11/88. Revised 5/17/88. Accepted 6/ 6/88.

This article has been cited by other articles:

				K A Skov Perspectives on the adaptive response from studies on the response to low radiation doses (or to cisplatin) in mammalian cells Human and Experimental Toxicology, July 1, 1999; 18(7): 447 - 451. [PDF]

				T. Yamada, R. Endo, M. Gotoh, and S. Hirohashi Identification of semaphorin E as a non-MDR drug resistance gene of human cancers PNAS, December 23, 1997; 94(26): 14713 - 14718. [Abstract] [Full Text] [PDF]